CANCER TEST
BREAST CANCER
SomArray Breast
Information
Questions
Turn Around Time:
2 weeks*
* If the sample needs to be enriched to ensure successful results, we will contact you
I Choose SomArray Breast Panel
With SomArray Breast we focus on the BRCA1 & BRCA2 genes as well as 9 additional genes that show statistically more frequent genetic instability in breast cancer.
Consult your Oncologist in order to get the best possible choice for you and a personalized treatment. Further personalization of exams is possible.
If your sample is not already in microDiagnostics Ltd files, Contact us immediately to arrange for safe and fast shipping to our laboratory.
You will also need to complete the Consent Form easily and quickly.
The number and type of mutations examined are updated through a dynamic process according to the current scientific research. It should therefore be recognized that there is a possibility that the list of genes in the order form may have changed (genes added or removed) when analyzing the sample in the laboratory.
If you have been diagnosed with breast cancer (a diagnosis based on histological examination), it is possible that the indications for determining the molecular profile of the cancer may be fulfilled. This molecular screening aims to detect whether the tumor shows mutations in the BRCA1, BRAC2 genes, as well as in other 9 genes closely associated with breast cancer.
According to NCCN’s (National Comprehensive Cancer Network) reports, breast cancer carrying mutations in the BRCA1 & BRCA2 genes is a candidate for treatment with PARPis, or PARP inhibitors.
The main indications for the SomArray Breast Exam are:
Triple Negative Breast Cancer [precursor expression of hormone receptors (estrogen- ER, progesterone- PR), & HER2, by Immunohistochemistry (IHC) in cancer’s sample embedded in a paraffin cube that resulted negative in all three biomarkers.
HER2-negative metastatic breast cancer (IHC)
The test is performed on the biopsy or surgical specimen (paraffin block) that your histological examination was conducted on.
Contact us to arrange safe and fast shipping to our laboratory.
You will also need to complete the Consent Form easily and quickly.
At our vertically integrated Laboratory, we handle your sample in such a way in order to minimize its unnecessary waste:
Your sample is processed once (and not repeatedly) by experienced histotechnologists, once its adequacy is checked by the Pathologist,
Material is consecutive obtained in such a way as in order to ensure diagnosis, Immunohistochemistry & molecular tests.
We’re gently handling the sample to ensure the highest possible amount of cancer cells, which could affect the validity of the results, a work that is performed by Pathologists.
Immediately the molecular biologist processes the sample in a completely controlled environment, with Next Generation Sequencing (NGS), or real time Polymerase Chain Reaction ( Real – time PCR) for the detection of mutations in genes of interest, or by the method of immunohistochemistry (IHC) on a certified platform to control the expression of tumor proteins.
Breast cancer is both a local-surgical disease and a systemic disease, which means a disease that can affect different parts of the body. In the treatment of breast cancer, the oncological goals are two:
The eradication of the disease from the breast
The eradication of the disease from the body
The first goal is achieved by surgery and radiation.
The second goal is achieved by systemic therapy, which means, medication.
Initial treatment is usually surgery that also makes the definitive diagnosis of cancer by histological examination.
The purpose of the surgical treatment is to exclude the entire tumor.
The correct and complete initial surgery is of great importance for the further development of the disease and should be done by a specialist in breast surgery.
Next, TNM staging is required [tumor size determination (T), lymph node metastasis (N) and detection of distant metastasis (M)] which is determined during the Histological Examination. The latter will be based on clinical staging.
Testing in order to determine whether the tumor expresses Hormone Receptors (Estrogen, Progesterone), HER2 biomarker and Ki67 cell proliferation marker. This is done by the method of Immunohistochemistry in the material of Histological Examination. The outcome will determine the oncologist’s treatment choice (See PredictArray Breast)
The choice of treatment is determined by the following parameters:
Histological examination
TNM staging
Test result whether the tumor expresses ER, PR and HER2 biomarker (See PredictArray Breast)
If the tumor carries mutations in the BRCA1 & BRCA2 genes (See SomArray Breast)
Consult your Oncologist for personalization of your treatment after diagnosis and / or surgical removal of the tumor.
Frequently Asked Questions (FAQ)
The main indications for the SomArray Breast Exam are:
Triple Negative Breast Cancer [precursor expression of hormone receptors (estrogen- ER, progesterone- PR), & HER2, by Immunohistochemistry (IHC) in cancer’s sample embedded in a paraffin cube that resulted negative in all three biomarkers.
HER2-negative metastatic breast cancer (IHC)
Contact us at 2310 23 22 72 and we will immediately arrange for your quick sample transfer to our laboratory.
Via bank card, bank deposit, or online bank deposit
One of the primary concerns of microDiagnostics’ Ltd is the protection of your personal data as well as the strict adherence to the conditions protecting your genetic material and medical results.
In full compliance with the General Data Protection Regulation (GDPR) we ensure that you are aware and conscious for any examination will be conducted and we do not announce results via phone calls.